Patents Issued in October 2, 2018
-
Patent number: 10085977Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: July 26, 2016Date of Patent: October 2, 2018Assignees: The Board of Trustees of the Univerity of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 10085978Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: August 22, 2016Date of Patent: October 2, 2018Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
-
Patent number: 10085979Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.Type: GrantFiled: November 30, 2015Date of Patent: October 2, 2018Assignee: IGNYTA, INC.Inventors: Zachary Dolph Hornby, Gang Li, David Wesley Anderson, Garrett M. Brodeur, Radhika Iyer
-
Patent number: 10085980Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.Type: GrantFiled: November 11, 2016Date of Patent: October 2, 2018Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Magali B. Hickey, Jennifer Vandiver
-
Patent number: 10085981Abstract: Embodiments of the present disclosure include compositions and pharmaceutical compositions that include protein acyl transferases (PAT) inhibitors, methods of treating a condition or disease, methods of treating autopalmitoylation activity, and the like.Type: GrantFiled: July 13, 2016Date of Patent: October 2, 2018Assignees: University of South Florida, Torrey Pines Institute for Molecular StudiesInventors: Robert Joseph Deschenes, Marcello Angelo Giulianotti, Richard Allen Houghten, David Allen Mitchell, Laura Dawn Hamel
-
Patent number: 10085982Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.Type: GrantFiled: March 26, 2015Date of Patent: October 2, 2018Assignee: ASTEX THERAPEUTICS LTDInventors: Eleonora Jovcheva, Timothy Pietro Suren Perera
-
Patent number: 10085983Abstract: Azabicyclo derivatives, a preparation process, and medical use thereof are provided. In particular, azabicyclo derivatives of formula (I), pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs thereof are described. The azabicyclo derivatives of formula (I) are useful as Epidermal Growth Factor Receptor (EGFR) inhibitors. The definitions of the variable R groups in the azabicyclo derivatives of formula (I) are described in the specification.Type: GrantFiled: September 24, 2015Date of Patent: October 2, 2018Assignees: Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd.Inventors: Yunzhou Jin, Ping Bu, Qi He, Jiong Lan, Fusheng Zhou, Liang Zhang, Xiangyu He
-
Patent number: 10085984Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.Type: GrantFiled: December 29, 2017Date of Patent: October 2, 2018Assignee: Viamet Pharmaceuticals (Bermuda), Ltd.Inventors: Steven Sparks, Christopher M. Yates, Sammy R. Shaver, William J. Hoekstra
-
Patent number: 10085985Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: July 22, 2016Date of Patent: October 2, 2018Assignee: AbbVie Inc.Inventors: Andrew Bogdan, Warren M. Kati, Keith F. McDaniel, Chang H. Park, George S. Sheppard, Le Wang
-
Patent number: 10085986Abstract: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: July 5, 2012Date of Patent: October 2, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Xiao-Ling Fan Cockcroft, William Farnaby, Natasha Kinsella, Kevin Merchant, David Miller
-
Patent number: 10085987Abstract: This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4-positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient.Type: GrantFiled: January 25, 2013Date of Patent: October 2, 2018Assignee: THOMAS JEFFERSON UNIVERSITYInventors: Michael P. Lisanti, Federica Sotgia
-
Patent number: 10085988Abstract: A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.Type: GrantFiled: September 19, 2016Date of Patent: October 2, 2018Assignees: SRI International, Trustees of Boston UniversityInventors: Tony Tianyi Wang, Shufeng Liu, Wenyu Wang, Neil Lajkiewicz, John A. Porco, Jr.
-
Patent number: 10085989Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: May 19, 2017Date of Patent: October 2, 2018Assignee: Novartis AGInventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
-
Patent number: 10085990Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.Type: GrantFiled: November 1, 2017Date of Patent: October 2, 2018Assignee: vTv Therapeutics LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
-
Patent number: 10085991Abstract: The present invention is directed to formulations comprising PVP polymer, a dispersion of a compound of Formula I (API), and citric acid, which formulations mitigate the effects of coadministering the compound of Formula I with a proton pump inhibitor compound.Type: GrantFiled: December 1, 2015Date of Patent: October 2, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Lei Zhu, Yvonne Cegielnik, Qun Lu
-
Patent number: 10085992Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.Type: GrantFiled: November 3, 2016Date of Patent: October 2, 2018Assignee: G1 Therapeutics, Inc.Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
-
Patent number: 10085993Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.Type: GrantFiled: July 22, 2015Date of Patent: October 2, 2018Assignee: Novartis AGInventors: Elisabete Goncalves, Christin Tauchmann, Shau-Fong Yen, Sudha Vippagunta, Zhixin Zong
-
Patent number: 10085994Abstract: A topical composition includes at least one film forming ingredient; at least one surfactant; at least one non-polar volatile siloxane solvent; at least 15% (w/w) water; and a therapeutically effective concentration of at least one pharmaceutical agent, wherein the composition is sufficiently designed to dry within 60 seconds after application to a body surface to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.Type: GrantFiled: March 10, 2014Date of Patent: October 2, 2018Assignee: PeriTech Pharma Ltd.Inventors: Evgenia Lozinsky, Eran Eilat
-
Patent number: 10085995Abstract: A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water, and a pharmaceutical agent selected from the group consisting of pramoxine, phenylephrine, hydrocortisone, salicylic acid, nitroglycerine, sildenafil, or their salts and combinations thereof, wherein the composition is sufficiently designed to dry within 60 seconds after application to the anorectal mucosa to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.Type: GrantFiled: June 16, 2015Date of Patent: October 2, 2018Assignee: PeriTech Pharma Ltd.Inventors: Evgenia Lozinsky, Eran Eilat
-
Patent number: 10085996Abstract: A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof and (b) a gonadorelin agonist and, optionally, (c) an antiestrogen agent, particularly for use in the treatment or prevention of a cancer; uses of such a combination in the preparation of a medicament for the treatment or prevention of a cancer; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a cancer in a subject comprising administering to said subject a therapeutically effective amount of such a combination.Type: GrantFiled: July 11, 2017Date of Patent: October 2, 2018Inventors: Samit Hirawat, Cristian Massacesi
-
Patent number: 10085997Abstract: The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.Type: GrantFiled: April 10, 2017Date of Patent: October 2, 2018Assignee: The Regents of the University of CaliforniaInventors: Richard L. Gallo, Teruaki Nakatsuji
-
Patent number: 10085998Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: June 28, 2016Date of Patent: October 2, 2018Assignee: Essentialis, Inc.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Patent number: 10085999Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: March 23, 2018Date of Patent: October 2, 2018Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Patent number: 10086000Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N?; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.Type: GrantFiled: December 1, 2015Date of Patent: October 2, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla, Chunhui Huang
-
Patent number: 10086001Abstract: The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.Type: GrantFiled: December 22, 2015Date of Patent: October 2, 2018Assignee: SciPharm SaRLInventors: Michael Freissmuth, Xaver Koenig, Christina Just
-
Patent number: 10086002Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.Type: GrantFiled: June 2, 2017Date of Patent: October 2, 2018Assignee: EMS S.A.Inventors: Giancarlo Santus, Leticia Khater Covesi, Luca Donadoni, Christina Ecclissato, Roberto Amazonas
-
Patent number: 10086003Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.Type: GrantFiled: November 15, 2016Date of Patent: October 2, 2018Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Claudio Cafiero, Leonardo Ortenzi
-
Patent number: 10086004Abstract: Dry powder formulations for inhalation containing a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.Type: GrantFiled: November 15, 2016Date of Patent: October 2, 2018Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio Cafiero, Leonardo Ortenzi, Francesca Schiaretti
-
Patent number: 10086005Abstract: A method of treating a subject suffering from an allergic disorder is provided, the method including inducing rapid desensitization to an allergen, the rapid desensitization effectuated by: administering to the subject a plurality of equal doses of a first anti-Fc?RI? monoclonal antibody, wherein the plurality of equal doses are administered over a 6 to 8 hour period and wherein each dose is lower than a level required to induce shock, thereby inducing rapid desensitization to the allergen. Monoclonal antibodies and methods of co-administering or consecutively administering a combination thereof to effectuate rapid desensitization are also provided.Type: GrantFiled: December 8, 2017Date of Patent: October 2, 2018Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
-
Patent number: 10086006Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.Type: GrantFiled: April 22, 2016Date of Patent: October 2, 2018Assignee: Zavante Therapeutics, Inc.Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
-
Patent number: 10086007Abstract: The present invention provides materials and methods for inducing ion secretion and/or for treating cystic fibrosis. In one embodiment, the composition comprises glucose and/or a non-metabolizable glucose analog and/or non-structural protein (NSP4), a NSP4 peptide, or a NSP4 toxoid as the active ingredient, formulated with pharmaceutically-acceptable carriers. In a preferred embodiment, the composition is in a form of an aerosol preparation for intranasal and/or pulmonary administration, and is used to stimulate chloride and fluid secretion in nasal, tracheal and/or bronchial epithelium.Type: GrantFiled: March 15, 2013Date of Patent: October 2, 2018Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Sadasivan Vidyasagar, Paul Okunieff, Sreekala Prabhakaran, Lurong Zhang
-
Patent number: 10086008Abstract: Described herein are topical anti-fungal pastes and methods that treat fungal infections of the skin, reduce the severity and duration of symptoms of fungal infections of the skin, and prevent recurrence of fungal infections. The topical pastes described herein are composed of an admixture of one or more antifungal agents, excipient inert powder, and a pharmaceutically acceptable topical carrier. The compositions and methods described herein minimize fungal resistance and maximize the number of targeted fungal strains. Additionally, the compounds and methods do not suppress the body's immune system either locally or systemically, thus allowing for a faster restoration of normal skin flora. The compositions and methods described herein are particularly suitable for use in infants and children as well as in immunocompromised individuals, diabetics, and the obese.Type: GrantFiled: October 6, 2014Date of Patent: October 2, 2018Assignee: Revolution Pharma LLCInventor: Craig W. Carver
-
Patent number: 10086009Abstract: This invention provides methods of enhancing brain development; increasing or enhancing intelligence; increasing or enhancing synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell, comprising contacting a subject or a pregnant or nursing mother thereof with a composition comprising an omega-3 fatty acid, an omega-6 fatty acid, and/or uridine, a metabolic precursor thereof, or a combination thereof.Type: GrantFiled: May 23, 2006Date of Patent: October 2, 2018Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGIESInventors: Richard J. Wurtman, Ingrid Richardson
-
Patent number: 10086010Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2?-deoxyuridine (fdU or foUdR) or a 5-formyl-2?-deoxyuridine derivative, optionally in combination with 5-hydroxy-2?-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2?-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2?-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.Type: GrantFiled: March 17, 2015Date of Patent: October 2, 2018Assignee: STC.UNMInventors: Yoshihiro Matsumoto, Alan Edward Tomkinson, Hiroshi Ide
-
Patent number: 10086011Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.Type: GrantFiled: August 7, 2017Date of Patent: October 2, 2018Assignee: Gilead Pharmasset LLCInventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
-
Patent number: 10086012Abstract: Provided herein are devices and methods for reversibly controlling memory function in living non-human animals. Some variations of methods for affecting memory function comprise temporarily inhibiting neurons of the hippocampus (e.g., neurons of the dorsal CA1 field of the hippocampus) during the acquisition or retrieval of a memory. Alternatively or additionally, methods for reversibly affecting memory function comprise inhibiting neurons of the amygdala (e.g. basolateral amygdala) and/or neurons of the cingulate cortex (e.g., anterior cingulated cortex). Methods for disrupting the formation and recall of memories by inhibiting excitatory neurons expressing light-activated proteins are disclosed herein. One or more methods for reversibly affecting memory function described herein can be used to evaluate the effectiveness of pharmacological agents in treating PTSD and/or various memory disorders.Type: GrantFiled: November 4, 2011Date of Patent: October 2, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karl Deisseroth, Inbal Goshen
-
Patent number: 10086013Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: GrantFiled: November 1, 2016Date of Patent: October 2, 2018Assignee: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 10086014Abstract: The invention relates to a method for the preparation of a polymer hydrogel, comprising cross-linking a precursor comprising a hydrophilic polymer optionally in combination with a second hydrophilic polymer, using a polycarboxylic acid as the cross-linking agent. The invention further concerns the polymer hydrogel obtainable by the method of the invention and the use thereof in a number of different applications.Type: GrantFiled: June 17, 2016Date of Patent: October 2, 2018Assignee: GELESIS LLCInventors: Alessandro Sannino, Luigi Ambrosio, Luigi Nicolais, Christian Demitri
-
Patent number: 10086015Abstract: Disclosed herein is a use of Fe3-?O4 nanoparticle in inhibiting the spore germination of Clostridium difficile. The Fe3-?O4 nanoparticle specifically targets the spores of Clostridium difficile spores by damaging and breaking the intact structure of the Clostridium difficile spores. Further, the Fe3-?O4 nanoparticle possesses superior sporicidal activity, as compared to other known bactericidal nanoparticles. Therefore, the Fe3-?O4 nanoparticle of the disclosure is useful as a bactericide or more specifically, a sporicide to treat Clostridium difficile infection for its superior sporicidal activity.Type: GrantFiled: July 17, 2015Date of Patent: October 2, 2018Inventor: Dar-Bin Shieh
-
Patent number: 10086016Abstract: The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition.Type: GrantFiled: March 4, 2016Date of Patent: October 2, 2018Assignee: CELYAD S.A.Inventors: Vinciane Gaussin, Roland Gordon-Beresford, Christian Homsy
-
Patent number: 10086017Abstract: A wound dressing makes use of polysaccharides, including the formation of a range of variable viscosity mixtures that use a solid polysaccharide such as medical grade cane sugar and a liquid polysaccharide such as honey, both of which have inherent beneficial properties for wound healing. The mixture is applied to an absorbent surface that is designed to absorb the mixed polysaccharide only partially.Type: GrantFiled: September 19, 2013Date of Patent: October 2, 2018Assignee: Medline Industries, Inc.Inventors: Debashish Chakravarthy, Andrew J. Ford
-
Patent number: 10086018Abstract: A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.Type: GrantFiled: December 30, 2016Date of Patent: October 2, 2018Inventor: Joseph E. Kovarik
-
Patent number: 10086019Abstract: The present invention provides a method to reduce insulin resistance and improve glucose tolerance by administering the probiotic bacterium Parabacteroides goldsteinii. This probiotic bacterium can therefore be used to treat insulin resistance, metabolic syndrome, and type 2 diabetes.Type: GrantFiled: October 23, 2017Date of Patent: October 2, 2018Assignee: CHANG GUNG BIOTECHNOLOGY CORP.Inventors: Yun-Fei Ko, Jan Martel, Tsung-Ru Wu, Chih-Jung Chang, Chuan-Sheng Lin, Jian-Ching Liau, Wei-Chang Wang, Chen-Yaw Chiu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, John D. Young
-
Patent number: 10086020Abstract: The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.Type: GrantFiled: March 8, 2018Date of Patent: October 2, 2018Assignee: 4D Pharma PLCInventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
-
Patent number: 10086021Abstract: Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.Type: GrantFiled: March 8, 2018Date of Patent: October 2, 2018Assignee: 4D Pharma PLCInventors: Ian Jeffery, Fergus Shanahan, Paul O'Toole, Alex Stevenson, Imke Mulder, Helene Savignac
-
Patent number: 10086022Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.Type: GrantFiled: March 8, 2018Date of Patent: October 2, 2018Assignee: 4D Pharma PLCInventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
-
Patent number: 10086023Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.Type: GrantFiled: March 8, 2018Date of Patent: October 2, 2018Assignee: 4D Pharma PLCInventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
-
Patent number: 10086024Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade neonicotinoids.Type: GrantFiled: December 15, 2016Date of Patent: October 2, 2018Inventor: Joseph E. Kovarik
-
Patent number: 10086025Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.Type: GrantFiled: June 19, 2017Date of Patent: October 2, 2018Assignee: QUORUM INNOVATIONS, LLCInventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
-
Patent number: 10086026Abstract: An herbal combination composition can include, herbal extracts, including combinations of: Hyssopus officinalis, Zingiber officinale, Viola odorata, Ziziphus jujuba, Chamomile, and Ocimum tenuiflorum; pharmaceutical compositions, including combinations of: dextromethorphan, guaifenesin, acetaminophen, phenylephrine, diphenhydramine; polyethylene glycol; propylene glycol; poloxamer 407; ethylenediaminetetraacetic acid; methyl paraben; potassium sorbate; propyl paraben; xanthan gum; citric acid; anhydrous citric; and purified acetate buffered water. Also disclosed is a method for manufacture of an herbal combination composition, including dissolving herbal extracts, adding poloxamer, adding pharmaceutical compositions, adding acetate buffer, adding xanthan gum gel, adding acetate buffer.Type: GrantFiled: June 27, 2016Date of Patent: October 2, 2018Inventor: Uwais M. Syed